Shilpa Biocare has secured a commercial supply agreement with Orion Corporation.
Through this Europe-wide agreement, Orion gains the exclusive right to distribute, market and sell Shilpa's recombinant human albumin, which is currently under development.
Meanwhile, Shilpa is eligible to receive development and regulatory milestone payments from Orion.
Shlipa's recombinant human albumin is a key plasma protein that can be used in various therapeutic applications, and is manufactured using a non-human, virus-free expression system.
According to Shilpa, the solution is safe, scalable and virus-free, addressing some of the key limitations associated with human-derived albumin.
“We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,” said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation.
“Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.”
“Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market," added Madhav Bhutada, Managing Director, Shilpa Biocare.
"This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.”
In a press release, Shilpa noted that it expected to see increased interest from biopharma innovators at this year's BIO Boston — particularly from smaller bioetch firms.
